Compare SOPA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPA | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.6M |
| IPO Year | 2021 | N/A |
| Metric | SOPA | RDHL |
|---|---|---|
| Price | $3.11 | $1.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 1.3M |
| Earning Date | 11-14-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,227,427.00 | ★ $9,550,000.00 |
| Revenue This Year | $26.32 | $381.91 |
| Revenue Next Year | $13.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.65 | ★ 157.62 |
| 52 Week Low | $0.64 | $0.91 |
| 52 Week High | $6.75 | $6.80 |
| Indicator | SOPA | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 66.52 |
| Support Level | $2.41 | $0.91 |
| Resistance Level | $4.46 | $1.42 |
| Average True Range (ATR) | 0.67 | 0.08 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 61.03 | 96.14 |
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.